With the ODYSSEY Outcomes Trial’s favorable pharmacoeconomic analysis now established—and a reduction in all-cause mortality with alirocumab— where do you see the evidence-based opportunities for these agents in your practice setting?

With the ODYSSEY Outcomes Trial’s favorable pharmacoeconomic analysis now established—and a reduction in all-cause mortality with alirocumab— where do you see the evidence-based opportunities for these agents in your practice setting?

CLICK HERE FOR CME CREDIT

With the ODYSSEY Outcomes Trial’s favorable pharmacoeconomic analysis now established—and a reduction in all-cause mortality with alirocumab— where do you see the evidence-based opportunities for these agents in your practice setting?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Michael H. Davidson, MD, FACC, FACP, FNLA

Michael H. Davidson, MD, FACC, FACP, FNLA

Clinical Professor

Clinical Professor
Director of Preventive Cardiology
The University of Chicago Hospitals and Clinic
Pritzker School of Medicine
Chicago, Illinois